7β-Hydroxycholesterol induces apoptosis and regulates cyclooxygenase 2 in head and neck squamous cell carcinoma

Archives of Otolaryngology - Head and Neck Surgery

Volumn 135, Issue 3, 2009, Pages 261-267

  Heiduschka, Gregor ^a   Erovic, Boban M ^a   Vormittag, Laurenz ^a   Skoda, Christiane ^a   Martinek, Helga ^a   Brunner, Markus ^a   Ehrenberger, Klaus ^a   Thurnher, Dietmar ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

7BETA HYDROXYCHOLESTEROL; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CHOLEST 5 EN 3 BETA,7 ALPHA DIOL; CHOLEST-5-EN-3 BETA,7 ALPHA-DIOL; CHOLESTEROL DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CELL PROLIFERATION; CELL STRAIN CAL27; CELL STRAIN FADU; CELL STRAIN SCC25; CELL STRAIN SCC9; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOSE RESPONSE; DRUG INHIBITION; GROWTH INHIBITION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IN VITRO SELECTION; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; WESTERN BLOTTING; CELL COUNT; COMPARATIVE STUDY; DRUG EFFECT; ENZYMOLOGY; FLOW CYTOMETRY; HEAD AND NECK TUMOR; IMMUNOHISTOCHEMISTRY; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL COUNT; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOOXYGENASE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; HEAD AND NECK NEOPLASMS; HUMANS; HYDROXYCHOLESTEROLS; IMMUNOHISTOCHEMISTRY;

EID: 63049087027     PISSN: 08864470     EISSN: 08864470     Source Type: Journal    
DOI: 10.1001/archoto.2008.558     Document Type: Article

References (38)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74-108.
2. Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl J Med. 2001;345(26):1890-1900.
3. Edwards BK, Brown ML, Wingo PA, et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancertreatment. J Natl Cancer Inst. 2005;97(19):1407-1427.
4. Brown AJ, Jessup W. Oxysterols and atherosclerosis. Atherosclerosis. 1999;142 (1):1-28.
5. Lea LJ, Hepburn PA, Wolfreys AM, Baldrick P. Safety evaluation of phytosterol esters, part 8: lack of genotoxicity and subchronic toxicity with phytosterol oxides. Food Chem Toxicol. 2004;42(5):771-783.
6. Biasi F, Leonarduzzi G, Vizio B, et al. Oxysterol mixtures prevent proapoptotic effects of 7-ketocholesterol in macrophages: implications for proatherogenic gene modulation. FASEB J. 2004;18(6):693-695.
7. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest. 1991;88(6):1785-1792.
8. Lizard G, Gueldry S, Sordet O, et al. Glutathione is implied in the control of 7-ke-tocholesterol-induced apoptosis, which is associated with radical oxygen species production. FASEBJ. 1998;12(15):1651-1663.
9. Ryan L, O'Callaghan YC, O'Brien NM. Generation of an oxidative stress precedes caspase activation during 7p-hydroxycholesterol-induced apoptosis in U937 cells. J Biochem Mol Toxicol. 2004;18(1):50-59.
10. Roussi S, Gosse F, Aoudé-Werner D, et al. Mitochondrial perturbation, oxidative stress and lysosomal destabilization are involved in 7g-hydroxysitosterol and 7 β-hydroxycholesterol triggered apoptosis in human colon cancercells. Apoptosis. 2007;12(1):87-96.
11. Lizard G, Miguet C, Besséde G, et al. Impairment with various antioxidants of the loss of mitochondrial transmembrane potential and of the cytosolic release of cytochrome coccuring during 7-ketocholesterol-induced apoptosis. Free Radic Biol Med. 2000;28(5):743-753.
12. Ryan L, O'Callaghan YC, O'Brien NM. The role of the mitochondria in apoptosis induced by 7g-hydroxycholesterol and cholesterol-5g,6g-epoxide. Br J Nutr. 2005; 94(4):519-525.
13. Miguet C, Monier S, Bettaieb A, et al. Ceramide generation occurring during 7 β- hydroxycholesterol-and 7 β-ketocholesterol-induced apoptosis is caspase independent and is not required to trigger cell death. Cell Death Differ. 2001; 8(1):83-99.
14. Agrawal S, Agarwal ML, Chatterjee-Kishore M, Stark GR, Chisolm GM. Stat1-dependent, p53-independent expression of p21(waf1) modulates oxysterol- induced apoptosis. Mol Cell Biol. 2002;22(7):1981-1992.
15. Miguet-Alfonsi C, PrunetC, Monier S, et al. Analysis of oxidative processes and of myelin figures formation before and afterthe loss of mitochondrial transmem brane potential during 7 β-hydroxycholesterol- and 7g-ketocholesterol-induced apoptosis: comparison with various pro-apoptotic chemicals. Biochem Pharmacol. 2002;64(3):527-541.
16. O'Callaghan YC, Woods JA, O'Brien NM. Characteristics of 7g-hydroxycholesterol- induced cell death in a human monocytic blood cell line, U937, and a human hepatoma cell line, HepG2. Toxicol In Vitro. 2002;16(3):245-251.
17. Roussi S, Winter A, Gosse F, et al. Different apoptotic mechanisms are involved in the antiproliferative effects of 7g-hydroxysitosterol and 7g-hydroxycholesterol in human colon cancer cells. Cell Death Differ. 2005;12(2):128-135.
18. Kang KA, Chae S, Lee KH, et al. Cytotoxic effect of 7g-hydroxycholesterol on human NCI-H460 lung cancercells. Biol Pharm Bull. 2005;28(8):1377-1380.
19. Maguire L, Konoplyannikov M, Ford A, Maguire AR, O'Brien NM. Comparison of the cytotoxic effects of g-sitosterol oxides and a cholesterol oxide, 7g- hydroxycholesterol, in cultured mammalian cells. Br J Nutr. 2003;90(4):767- 775.
20. Cheng KP, Nagano H, Luu B, Ourisson G, Beck JP. Chemistry and biochemistry of Chinese drugs, part I: sterol derivatives cytotoxic to hepatoma cells, isolated- from the drug Bombyx cum Botryte. J Chem Res. 1977;217:2501-2521.
21. Dimberg J, Samuelsson A, Hugander A, Soderkvist P. Differential expression of cyclooxygenase 2 in human colorectal cancer. Gut. 1999;45(5):730-732.
22. Sano H, Kawahito Y, Wilder RL, et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res. 1995;55(17):3785-3789.
23. Tucker ON, Dannenberg AJ, Yang EK, et al. Cyclooxygenase-2 expression is up- regulated in human pancreatic cancer. Cancer Res. 1999;59(5):987-990.
24. Chan G, Boyle JO, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res. 1999;59(5): 991-994.
25. Erovic BM, Pelzmann M, Turhani D, et al. Differential expression pattern of cy- clooxygenase-1 and -2 in head and neck squamous cell carcinoma. Acta Otolaryngol. 2003;123(8):950-953.
26. Dannenberg AJ, Altorki NK, Boyle JO, et al. Cyclo-oxygenase 2: a pharmacological target forthe prevention of cancer. Lancet Oncol. 2001;2(9):544-551.
27. Leers MP, Kolgen W, Bjorklund V, et al. Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol. 1999;187(5):567-572.
28. Cohen EE, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2003; 21(10):1980-1987.
29. Cohen EE, Kane MA, List MA, et al. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res. 2005;11(23):8418-8424.
30. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol. 2004;22(1):77-85.
31. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous- cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567-578.
32. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994;107(4):1183-1188.
33. Soslow RA, Dannenberg AJ, Rush D, et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer. 2000;89(12):2637-2645.
34. Bresalier RS, Sandler RS, Quan H, et al; Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofe- coxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352 (11):1092-1102.
35. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med. 2004;351(17): 1709-1711.
36. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med. 2005; 352(11):1081-1091.
37. Solomon SD, McMurray JJ, Pfeffer MA, et al; Adenoma Prevention with Cele- coxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352 (11):1071-1080.
38. Grösch S, Maier TJ, Schiffmann S, Geisslinger G. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst. 2006;98(11):736-747.